Clinical Trials Logo

Clinical Trial Summary

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabetes (T1D) who have been having low blood sugars ("hypos") at night. ZT-01 increases the amount of a hormone called glucagon during low blood sugar, and this may help prevent the occurrence of hypos. The main questions this trial aims to answer are whether ZT-01 lowers the number of hypos happening at night, and what its effects are on blood sugar levels. The safety of ZT-01 will also be measured. Participants will be asked to wear a study-provided continuous glucose monitor (CGM) during two 4-week periods when they will self-inject the study drug before bed. They will get ZT-01 at one of three dose levels during one period, and placebo (which looks like the study drug but doesn't contain the active ingredient) during the other. Neither the participant nor the study site will know what they are receiving during each treatment period or see data from the CGM. The participant will continue to use their usual methods of measuring blood sugar (including their personal CGM) and giving insulin during the study. The participant will be asked to complete a short diary each evening, and will be asked to upload the CGM data to a study phone every day. If a participant uses their own CGM and is willing to share information on how often they have low blood sugar with the study site at the first visit to see if they meet study entry requirements, they will have 6 study visits, 2 study phone calls, and be in the study for about 16 weeks. If they don't use CGM or don't want to share their information, then they will be asked to wear a study CGM for an extra 4 weeks to find out how many low blood sugars they have, and will have an extra visit. Study participants will be asked to give blood and urine for testing to see whether they meet the requirements to enter the study, and at the start and end of each treatment period to see if the study treatment has any effects. They will also have their blood pressure and temperature taken at each study visit, and have an ECG at 4 visits to measure the electrical activity of their heart. Some participants will be asked to also take part in a sub-study where their blood level of ZT-01 and glucagon is measured, after the first and last dose. They will be asked to stay at the study site overnight for each set of measurements (4 in total).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05762107
Study type Interventional
Source Zucara Therapeutics Inc.
Contact
Status Recruiting
Phase Phase 2
Start date July 28, 2023
Completion date July 2025

See also
  Status Clinical Trial Phase
Completed NCT04712266 - A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes Early Phase 1
Recruiting NCT05967260 - DailyDose Smart Snack Study for T1D on MDI N/A
Completed NCT06097689 - A Pilot Study to Assess the Feasibility of a Novel Non-invasive Technology to Measure Changing Blood Glucose Levels in Adults With Type-1 Diabetes Mellitus N/A
Completed NCT03286816 - The Effect of Intravenous Lactate on Brain Lactate Concentrations During Hypoglycemia N/A
Recruiting NCT05221359 - Pilot Study Evaluating Safety of ExOlin® in Patients With Poorly Controlled Type 1 Diabetes N/A
Recruiting NCT06382350 - Glycemic Excursions in Patients With Type 1 Diabetes Mellitus Using Closed-loop Systems
Recruiting NCT04266379 - Efficacy of Closed-loop Insulin Therapy in Adults Prone to Hypoglycemia N/A
Completed NCT03163511 - A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness Phase 1/Phase 2
Active, not recruiting NCT04614168 - Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes N/A
Completed NCT03028220 - Impact on Hypoglycaemia Awareness of Real Time CGM and Intermittent Continuous Glucose Data N/A
Enrolling by invitation NCT04233138 - SUPPORT Online Training Platform for Type 1 Diabetes Self-management Education and Support (SUPPORT) N/A
Recruiting NCT04664764 - Intermediate and Long Acting Insulin Young Children Type 1 Diabetes. Phase 4